Home › Trial NCT07217119
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM
- Trial IDNCT07217119
- StatusActive Not Recruiting
- PhasePhase 1/2
- Study typeInterventional
- SponsorGlaxoSmithKline
- Enrollment25
- Start date2019-11-26
- ConditionsMultiple Myeloma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.